Home Newsfeeds RBC Capital Maintains Outperform on Meta Platforms, Lowers Price Target to $190

RBC Capital Maintains Outperform on Meta Platforms, Lowers Price Target to $190

RBC Capital analyst Brad Erickson maintains Meta Platforms (NASDAQ:META) with a Outperform and lowers the price target from $200 to $190.

byBenzinga Newsdesk

July 28, 2022

1 minute read

RBC Capital analyst Brad Erickson maintains Meta Platforms (NASDAQ:META) with a Outperform and lowers the price target from $200 to $190.

Analyst Ratings

Evaluating Immunome: Insights From 4 Financial Analysts

By Benzinga Insights

May 31, 9:00 AM

In the preceding three months, 4 analysts have released ratings for Immunome (NASDAQ:IMNM), presenting a wide array of…

IMNM

News

Advanced Health Intelligence Bagged Exclusive License Deal with Changlin Network Technology Ltd; Involves $10M In Upfront Payment

By Benzinga Newsdesk

August 4, 5:11 AM

Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ:AHI) (the “Company”) is pleased to inform shareholders that the Company has executed a binding exclusive, perpetual license with Shanghai-based Changlin

AHI

Eli Lilly Stock Is Tumbling Today – Here’s Why

By Vandana Singh

December 11, 1:02 PM

Eli Lilly And Co (NYSE: LLY) announced the detailed results from the SURMOUNT-4 Phase 3 study evaluating the safety and efficacy of Zepbound (tirzepatide) compared to a placebo for obesity with weight-related comorbidities,

LLY